Lomecel-B is a cell therapy commercialized by Longeveron, with a leading Phase II program in Ageing. According to Globaldata, it is involved in 13 clinical trials, of which 7 were completed, 3 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Lomecel-B’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lomecel-B is expected to reach an annual total of $11 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Lomecel-B is under development for the treatment of ageing frailty, hypoplastic left heart syndrome in infants, unspecified influenza virus infections and Alzheimer's disease. It is administered through intramyocardial and intravenous route. The drug candidate comprises of allogeneic human mesenchymal stem cells (hMSC).
It was under development for the treatment of acute respiratory distress syndrome caused by coronavirus disease 2019 (COVID-19).
Longeveron is a biotechnology company. It discovers and develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product LOMECEL-B, a cell-based therapy against aging-related chronic diseases. It is also conducting clinical research in the following indications/conditions: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Longeveron works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company operates through manufacturing plants in Miami, Florida, the US. Longeveron is headquartered in West Palm Beach, California, the US.
The company reported revenues of (US Dollars) US$1.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 76.8% over FY2020. The operating loss of the company was US$17.2 million in FY2021, compared to an operating loss of US$3.8 million in FY2020. The net loss of the company was US$17.1 million in FY2021, compared to a net loss of US$3.7 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 43.1% over the previous quarter.
For a complete picture of Lomecel-B’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.